7XB0 Stock Chart & Stats
€0.80
<€0.01(1.01%)
―
--
Day’s Range― - ―
52-Week Range€0.45 - €3.78
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.00
Market Cap
€17.88M
Enterprise Value€232.63
Total Cash (Recent Filing)€49.50M
Total Debt (Recent Filing)€63.71M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding20,605,349
10 Day Avg. Volume25
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-39.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.18
Revenue Forecast (FY)€16.77M
Bulls Say, Bears Say
Bulls Say
Supportive Balance Sheet With Low LeverageLow current leverage and sizable equity create durable financial headroom to fund development and commercialization needs. This reduces near-term refinancing risk and gives management flexibility to pursue partnerships or manufacturing scale-up even while operations remain cash-consuming.
Biosimilars And Partnering-focused Business ModelA business model centered on biosimilars plus upfront, milestone and royalty partnering is structurally durable: it spreads development risk, creates multi-stage revenue potential, and leverages partner capabilities for commercialization, reducing standalone capital and execution burden over time.
Process Development And Manufacturing ExpertiseIn-house process development and manufacturing strategy are durable competitive assets for a biosimilar developer. They lower unit costs, shorten scale-up timelines, and make the company a more attractive partner, supporting margin sustainability and faster commercialization when regulatory approvals occur.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained large cash burn forces reliance on external financing or equity raises, increasing dilution risk and potentially constraining R&D or commercialization investments. Over months this pressure can force program prioritization, slowing launches and weakening competitive positioning.
Ongoing Operating Losses And Weak ProfitabilityRepeated operating losses and a deteriorating gross profit signal the core business hasn’t achieved sustainable margins. This undermines long-term viability absent structural cost or revenue improvements, meaning future growth may not translate into durable profitability without operational changes.
Volatile Revenue And Recent Multi-year DeclinesRevenue volatility and prior multi-year declines reflect dependence on milestone timing and uneven commercialization. Such variability complicates cash planning and partnership revenue predictability, increasing execution risk for product launches and making sustained growth harder to rely on over the next 2–6 months.
Xbrane Biopharma AB News
7XB0 FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was €0.45 and its highest was €3.77 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is €17.88M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Oct 30, 2026 which is in 75 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Jul 17, 2026. The company reported -€0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.05.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Undervalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -€0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in DE:7XB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.